TUDCA
9 benefits mapped to clinical evidence across supplements.
Dose per serving from products
170 products in our catalogue print how much TUDCA a serving holds.
Most common: 1 g to 2.5 g, 28% of 170 products.
| Dose per serving | Products |
|---|---|
| 50 mg or less | 7 |
| 50 mg to 100 mg | 8 |
| 100 mg to 250 mg | 28 |
| 250 mg to 500 mg | 44 |
| 500 mg to 1 g | 34 |
| 1 g to 2.5 g | 48 |
| over 2.5 g | 1 |
Dose per serving from research
12 study groups in 8 studies say how much TUDCA participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 1 g to 2.5 g, 50% of 12 study groups.
| Daily dose | Study groups |
|---|---|
| 250 mg to 500 mg | 2 |
| 500 mg to 1 g | 4 |
| 1 g to 2.5 g | 6 |
Benefit Evidence
Neuroprotection, less inflammation
ALS decline slowed +0.42/month
Survival +6.5 months
Neuroprotection, less inflammation
ALS decline slowed +0.42/month
Survival +6.5 months
Research sources
Brain health (3)
- Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis
PubMed ID: 25664595
Phase II ALS RCT: TUDCA slowed functional decline, supporting neuroprotective/brain support effects.
- Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis
PubMed ID: 32877582
Taurursodiol combination slowed ALS progression over 24 weeks in humans (functional benefit).
- Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis
PubMed ID: 33063909
Survival analysis: longer median survival with early taurursodiol exposure, supporting clinical neuro benefit.
Cell health (3)
- Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis
PubMed ID: 33063909
Survival analysis: participants on taurursodiol-containing treatment lived longer, supporting neuro/cellular benefit.
- Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis
PubMed ID: 25664595
Phase II ALS trial: one‑year TUDCA slowed functional decline, consistent with cellular neuroprotection.
- Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis
PubMed ID: 32877582
Taurursodiol combination slowed ALS functional decline over 24 weeks (human RCT).
Nerve health (3)
- Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis
PubMed ID: 32877582
Taurursodiol combination slowed ALS progression in a 24‑week RCT (human clinical neuro benefit).
- Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis
PubMed ID: 25664595
Phase II ALS RCT: one‑year TUDCA significantly slowed ALS functional decline — strong human evidence for neuronal support.
- Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis
PubMed ID: 33063909
Survival benefit analysis: earlier taurursodiol exposure associated with longer median survival in ALS cohort.
Liver support (2)
- A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis
PubMed ID: 27893675
24‑week non‑inferiority RCT in PBC: TUDCA non‑inferior to UDCA for ALP reduction; some symptomatic improvement.
- Tauroursodeoxycholic acid for the treatment of HCV-related chronic hepatitis: a multicenter placebo-controlled study
PubMed ID: 9840118
Large multicenter RCT in HCV hepatitis: TUDCA significantly lowered aminotransferases vs placebo.
Inflammation (2)
- Bile acid metabolites predict multiple sclerosis progression and supplementation is safe in progressive disease
PubMed ID: 39447576
MS trial: immune cell shifts (reduced central memory CD4+ and Th1/17) suggest anti‑inflammatory immunomodulation.
- Tauroursodeoxycholic acid for the treatment of HCV-related chronic hepatitis: a multicenter placebo-controlled study
PubMed ID: 9840118
HCV RCT: reductions in aminotransferases reflect reduced hepatic inflammation.
Antioxidant (2)
- Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis
PubMed ID: 32877582
Taurursodiol combination showed slowed ALS progression, consistent with reduced neuronal cell stress.
- Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis
PubMed ID: 25664595
ALS clinical trial effects align with TUDCA's putative ER stress‑relieving, cytoprotective mechanisms.
Detoxification (1)
- Tauroursodeoxycholic acid for the treatment of HCV-related chronic hepatitis: a multicenter placebo-controlled study
PubMed ID: 9840118
HCV RCT: lowered aminotransferases indicating reduced hepatic injury and improved clearance of toxic bile/metabolites.
Digestive support (1)
- Acupoint Catgut Embedding as Adjunctive Therapy for Patients With Gallstones
PubMed ID: 33471487
TUDCA improved symptom scores in functional gallbladder patients (though GBEF unchanged without adjunctive ACE).
Immune support (1)
- Bile acid metabolites predict multiple sclerosis progression and supplementation is safe in progressive disease
PubMed ID: 39447576
Randomized MS trial showed TUDCA raised bile acids and altered immune cell populations vs placebo.
Similar by evidence
Supplements the same benefits carry qualifying findings for — a fact about the evidence graph, not a recommendation to swap.
Products with TUDCA
Search all262 products whose verified label declares TUDCA — not every bottle that mentions it in a title.